Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
PolyPeptide Group AG ( (CH:PPGN) ) just unveiled an update.
PolyPeptide Group AG has announced a strategic alliance with Lupin Manufacturing Solutions to enhance supply chain resilience and operational efficiency in the peptide manufacturing sector, particularly for metabolic therapies. This collaboration aims to meet the growing demand for peptide supply, ensuring reliable access to specialized materials and supporting the long-term growth of both companies, while maintaining high standards of quality and compliance.
The most recent analyst rating on (CH:PPGN) stock is a Hold with a CHF22.00 price target. To see the full list of analyst forecasts on PolyPeptide Group AG stock, see the CH:PPGN Stock Forecast page.
More about PolyPeptide Group AG
PolyPeptide Group AG is a specialized Contract Development & Manufacturing Organization (CDMO) focused on peptide-based active pharmaceutical ingredients, serving primarily the pharmaceutical and biotech industries. With a global network of GMP-certified facilities, the company supports drug therapies across various stages, with significant exposure to metabolic diseases.
Average Trading Volume: 39,158
Technical Sentiment Signal: Sell
Current Market Cap: CHF814.2M
Learn more about PPGN stock on TipRanks’ Stock Analysis page.